Cite
Braciak TA, Roskopf CC, Wildenhain S, et al. Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. Oncoimmunology. 2018;7(9):e1472195doi: 10.1080/2162402X.2018.1472195.
Braciak, T. A., Roskopf, C. C., Wildenhain, S., Fenn, N. C., Schiller, C. B., Schubert, I. A., Jacob, U., Honegger, A., Krupka, C., Subklewe, M., Spiekermann, K., Hopfner, K. P., Fey, G. H., Aigner, M., Krause, S., Mackensen, A., & Oduncu, F. S. (2018). Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. Oncoimmunology, 7(9), e1472195. https://doi.org/10.1080/2162402X.2018.1472195
Braciak, Todd A, et al. "Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells." Oncoimmunology vol. 7,9 (2018): e1472195. doi: https://doi.org/10.1080/2162402X.2018.1472195
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS. Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018. PMID: 30228941; PMCID: PMC6140553.
Copy
Download .nbib